



PRESS RELEASE

Code: 01BIAC/03
For Immediate Release!

For further information, please contact:

Dr Ulf Jönsson, President
+46 (0) 18 67 57 00

Scientific/Trade Press Enquiries:

Debbie Staines, HCC.De Facto Group
+44 (0) 207 496 3300

Biacore Awarded Damages in Patent Dispute

Estimated amount: USD 1.7 million

Uppsala, Sweden, April 27, 2001. Biacore International AB (Biacore) (SSE: BCOR; Nasdaq: BCOR) today announced that, on April 23, 2001, the U.S. District Court for the District of Delaware granted a permanent injunction preventing Thermo Bioanalysis Corp (Thermo) from infringing Biacore's patent (U.S. patent no. 5,436,161). Furthermore, the Court awarded damages in favor of Biacore AB and Biacore Inc. to be calculated based upon a royalty rate of 40% of the sales price of each IAsys biosensor sold by Thermo since July 25, 1995, plus interest.

Although the final amount due to Biacore has not been determined at this time, it is estimated to be in the region of USD 1.7 million.

The decision of the Court can be appealed to the Court of Appeals for the Federal Circuit, the centralized appellate Court for patent appeals in the United States.

Background

On December 30, 1999, the U.S. District Court for the District of Delaware announced its decision in the patent dispute between Biacore and Thermo. The Court decided in Biacore's favor, holding that Biacore's patent was valid and that the patent had been infringed by Thermo's Affinity Sensors unit. The Court further indicated that it "would grant a permanent injunction preventing Thermo from infringing the '161 patent' and requested further briefing regarding the amount of damages to be paid by Thermo for its past infringement and concerning the language of the permanent injunction. The Court's April 23, 2001 Judgment addressed these outstanding issues.

– Ends –

This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Notes to editors:

Biacore is a global market leader in Surface Plasmon Resonance (SPR) based technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. The company currently has six systems on the market with its BIACORE®3000 system offering specific application in drug discovery processes upstream of high-throughput screening (HTS). A new high-performance system is currently under late-stage development and will focus on applications downstream of HTS.

Based in Uppsala, Sweden, the company is listed on the Stockholm Stock Exchange and Nasdaq in the U.S. In 2000 the company has sales of SEK 438.8 million and an operating income of SEK 78.0 million.

Further information on Biacore can be found on the web: www.biacore.com

Address and phone:

*Biacore International AB
Rapskatan 7, SE-754 50 Uppsala, SWEDEN
Phone: +46 (0)18-675700 Fax: +46 (0)18-150111
info@biacore.com*